Crinetics Pharmaceuticals (CRNX) Projected to Post Earnings on Tuesday

Crinetics Pharmaceuticals (NASDAQ:CRNX) will likely be releasing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($1.18) per share and revenue of $14.8420 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same period in the previous year, the business posted ($1.04) EPS. The business’s revenue for the quarter was up 2873.4% on a year-over-year basis. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Stock Performance

Crinetics Pharmaceuticals stock opened at $83.52 on Monday. The company has a market capitalization of $8.81 billion, a PE ratio of -16.28 and a beta of 0.23. Crinetics Pharmaceuticals has a fifty-two week low of $25.83 and a fifty-two week high of $84.00. The firm has a 50 day moving average price of $54.15 and a 200 day moving average price of $46.18.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, Director Coelho Rogerio Vivaldi sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the sale, the director owned 19,225 shares in the company, valued at $769,000. This represents a 13.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total value of $246,123.00. Following the completion of the sale, the director directly owned 6,400 shares in the company, valued at $228,288. This represents a 51.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mackenzie Financial Corp acquired a new stake in Crinetics Pharmaceuticals in the third quarter valued at approximately $247,000. Jain Global LLC acquired a new position in Crinetics Pharmaceuticals during the 3rd quarter worth approximately $247,000. Brooklyn Investment Group grew its holdings in Crinetics Pharmaceuticals by 14,878.4% during the 3rd quarter. Brooklyn Investment Group now owns 5,542 shares of the company’s stock worth $231,000 after acquiring an additional 5,505 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Crinetics Pharmaceuticals in the 4th quarter valued at approximately $230,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Crinetics Pharmaceuticals in the 4th quarter valued at approximately $224,000. 98.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CRNX shares. Oppenheimer restated a “market perform” rating on shares of Crinetics Pharmaceuticals in a research report on Tuesday, July 7th. Piper Sandler downgraded Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Cantor Fitzgerald lowered Crinetics Pharmaceuticals from an “overweight” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Friday, July 17th. Finally, Lifesci Capital cut Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $81.00.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.